A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer

Journal of Supportive Oncology

Volumn 11, Issue 1, 2013, Pages 31-42

  Lesser, Glenn J ^a   Case, Doug ^a   Stark, Nancy ^a   Williford, Susan ^b   Giguere, Jeff ^c   Astrid Garino, L ^d   Naughton, Michelle J ^a   Vitolins, Mara Z ^a   Lively, Mark O ^a   Shaw, Edward G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Emerywood Hematology and Oncology   (United States)

^c Cancer Centers of the Carolinas   (United States)

^d Metro Minnesota CCOP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; PLACEBO; UBIDECARENONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; UBIQUINONE; VITAMIN;

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER RADIOTHERAPY; CAUCASIAN; CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST CANCER INSTRUMENT; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE TOOL; HISPANIC; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MOOD STATES FATIGUE QUESTIONNAIRE; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; FATIGUE; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PROGNOSIS; QUALITY OF LIFE; UTILIZATION REVIEW; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PARTICIPATION; PROGNOSIS; QUALITY OF LIFE; SELF REPORT; UBIQUINONE; VITAMINS;

MLCS; MLOWN;

EID: 84879326542     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40-50.
2. Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancerrelated fatigue: a practical review. Ann Oncol. 2011;22(6):1273-1279.
3. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353-360.
4. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997;34(3)(suppl 2):4-12.
5. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancerrelated fatigue: evolving concepts in evaluation and treatment. Cancer. 2003;98(9):1786-1801.
6. Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist. 2003;8(suppl 1):5-9.
7. Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(5):1319-1328.
8. Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: a comparison with the fatigue experienced by healthy individuals. Cancer Nurs. 1994;17(5):367-378.
9. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage. 1999;18(4):233-242.
10. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(suppl 1):4-10.
11. Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer. 2008;16(7):791-801.
12. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Eur J Cancer Care (Engl). 1996;5(suppl 2):8-23.
13. So WK, Marsh G, Ling WM, et al. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum. 2009;36(4):E205-E214.
14. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743-753.
15. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751-758.
16. Cella D, Davis K, Breitbart W, Curt G; for the Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385-3391.
17. Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(suppl 11):2565-2576.
18. Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med. 1998;21(1):1-18.
19. Janz NK, Mujahid M, Chung LK, et al. Symptom experience and quality of life of women following breast cancer treatment. J Womens Health (Larchmt). 2007;16(9):1348-1361.
20. Loscalzo MJ, Clark KL. Problem-related distress in cancer patients drives requests for help: a prospective study. Oncology (Williston Park). 2007;21(9):1133-1138.
21. Berger A, Abernethy A, Atkinson A. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2011. www.nccn.org/professionals/ physician_gls/pdf/fatigue.pdf. Accessed July 4, 2011.
22. Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol. 2008;26(23):3886-3895.
23. Mortimer JE, Barsevick AM, Bennett CL, et al. Studying cancerrelated fatigue: report of the NCCN Scientific Research Committee. J Natl Compr Canc Netw. 2010;8(12):1331-1339.
24. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91(5):822-828.
25. Escalante CP, Manzullo EF. Cancer-related fatigue: the approach and treatment. J Gen Intern Med. 2009;24(suppl 2):S412-S416.
26. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100(16): 1155-1166.
27. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer. 2008;44(8):1097-1104.
28. 10: a new drug for myocardial ischemia? Med Clin North Am. 1988;72(1):243-258.
29. 10 for cardiomyopathy. Klin Wochenschr. 1988;66(13):583-590.
30. 10 in health and disease. Eur J Clin Nutr. 1999;53(10):764-770.
31. Forsmark-Andrée P, Lee CP, Dallner G, Ernster L. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic Biol Med. 1997;22(3):391-400.
32. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta. 1957;25(1): 220-221.
33. Crane FL, Navas P. The diversity of coenzyme Q function. Mol Aspects Med. 1997;18(suppl):S1-S6.
34. Crane FL, Sun IL, Sun EE. The essential functions of coenzyme Q. Clin Investig. 1993;71(suppl 8):S55-S59.
35. 10. Am J Health Syst Pharm. 1999;56(6): 519-521.
36. 10. J Am Coll Nutr. 2001;20(6):591-598.
37. 10 concentrations and redox state in apparently healthy children and adults. Clin Chim Acta. 2004;347(1-2):139-144.
38. 10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. Clin Chim Acta. 2003;332(1-2):123-132.
39. 10 in patients with congestive heart failure. Ann Intern Med. 2000;132(8):636-640.
40. 10 in isolated systolic hypertension. South Med J. 2001;94(11):1112-1117.
41. 10in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
42. 10levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol. 2006;54(2):234-241.
43. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun. 1998;247(1):166-170.
44. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem. 1997;250(1):66-73.
45. 10 in human plasma as a possible marker of oxidative stress. J Lipid Res. 1996;37(1):67-75.
46. Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig. 1993;71(suppl 8):S60-S65.
47. 10 Drug Surveillance Investigators. Mol Aspects Med. 1994;15(suppl):S287-S294.
48. 10tolerability in Huntington's disease. Mov Disord. 1996;11(3):321-323.
49. 10. Int J Tissue React. 1990;12(3):169-171.
50. 10therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71(suppl 8):S134-S136.
51. 10 Study Group. J Card Fail. 1995;1(2):101-107.
52. 10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18(suppl):S159-S168.
53. 10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004:27(5):295-299.
54. 10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-149.
55. 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297-306.
56. 10 deficiencies. Biofactors. 2008;32(1-4):113-118.
57. 10 deficiency. FASEB J. 2008;22(6):1874-1885.
58. 10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. 2008;5:8.
59. Laaksonen R, Fogelholm M, Himberg JJ, Laakso J, Salorinne Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur J Appl Physiol Occup Physiol. 1995;72(1-2):95-100.
60. Malm C, Svensson M, Ekblom B, Sjödin B. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand. 1997;161(3):379-384.
61. 10 affect aerobic capacity in endurance athletes? Int J Sport Nutr. 1997;7(3):197-206.
62. 10 on the exercise tolerance of middle-aged, untrained men. Int J Sports Med. 1995;16(7):421-427.
63. 2max, and lipid peroxidation in trained cyclists. Int J Sport Nutr. 1991;1(4): 353-365.
64. 10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15(suppl):S207-S212.
65. 10 in cardiotoxicity induced by adriamycin [in Japanese]. Gan To Kagaku Ryoho. 1984;11(3):502-508.
66. 10 amongst breast cancer patients. Am J Health Behav. 2006;30(3):313-321.
67. Sadler IJ, Jacobsen PB. Progress in understanding fatigue associated with breast cancer treatment. Cancer Invest. 2001;19(7):723-731.
68. Jacobsen PB, Stein K. Is fatigue a long-term side effect of breast cancer treatment? Cancer Control. 1999;6(3):256-263.
69. McNair DM, Lorr M. An analysis of mood in neurotics. J Abnorm Psychol. 1964;69:620-627.
70. McNair DM, Lorr M, Droppleman L. Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service; 1971.
71. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
72. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63-74.
73. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, version 4. Evanston, IL: Evanston Northwestern Healthcare; 1997.
74. Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression in a community sample. Am J Psychiatry. 1980;137(9):1081-1084.
75. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705-714.
76. Hess D, Keller HE, Oberlin B, Bonfanti R, Schüep W. Simultaneous determination of retinol, tocopherols, carotenes and lycopene in plasma by means of high-performance liquid chromatography on reversed phase. Int J Vitam Nutr Res. 1991;61(3):232-238.
77. 10 in humans. Scand J Clin Lab Invest. 1999;59(6):457-466.
78. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. New York, NY: John Wiley & Sons; 2004:122-137.
79. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010;116(3):766-774.
80. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673-3679.
81. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase III randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program research base study. Cancer. 2010;116(14):3513-3520.
82. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7(7):CD006704.
83. 10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther. 1998;36(9):506-509.
84. 10 in Parkinson disease. Arch Neurol. 2007;64(7):938-944.
85. 10 in patients with Parkinson's disease. Exp Neurol. 2004;188(2):491-494.
86. 10 in ALS. Neurology. 2005;65(11):1834-1836.
87. 10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. 2006;44(3):212-218.
88. 10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404.